Related Experiment Video
Updated: Nov 23, 2025
Assessment of the Metabolic Profile of Primary Leukemia Cells
Published on: November 21, 2018
Leucopenia associated with metamizole: a case-control study
Lea Blaser1, Hala Hassna1, Sarah Hofmann1
1Division of Clinical Pharmacology and Toxicology, University and University Hospital Basel, Switzerland.
Aims Of The Study:
The aim of this study was to identify possible risk factors for the development of leucopenia associated with metamizole use.
Methods:
A retrospective case-control study was performed. Cases of metamizole-associated leucopenia managed at a single centre (2005-2013) were characterised and compared with matched controls who took metamizole without developing complications.
Results:
Fifty-seven cases and 139 controls were identified. Of the cases, 32 were postoperative and these were compared to age-, sex- and ward-matched postoperative controls (n = 64). The remaining cases (n = 25) were compared to sex-matched, non-postoperative controls (n = 75). The number of patients with a positive allergy history was higher among postoperative cases than controls (p = 0.004) as was the number with previous leucopenic episodes (p = 0.03). The prevalence of diagnosed hepatitis C infection was 9% among all cases compared with 1% among all controls (p = 0.005). The use of concomitant cytostatic agents (even at immunosuppressive doses) was significantly higher among non-postoperative cases than controls (p = 0.011). There was no association between renal function and the development of leucopenia.
Conclusions:
A history of allergies, previous leucopenic episodes, hepatitis C infection and concomitant cytostatic agents are possible risk factors for leucopenia associated with metamizole use.
